Augurex Life Sciences Corp.

Augurex Life Sciences Corp. Augurex is a clinical diagnostics leader advancing biomarker-driven solutions for the early detection and management of autoimmune diseases.

Augurex is a clinical diagnostics leader advancing biomarker-based tests for autoimmune diseases, enabling earlier, more precise detection and disease management to improve patient outcomes. Our lead products include JOINTstat® (14-3-3eta), which supports the diagnosis and monitoring of rheumatoid arthritis (RA), and SPINEstat™ (Anti-14-3-3eta Multiplex), a first-in-class blood test that aids in the diagnosis of axial spondyloarthritis (axSpA) and helps distinguish it from mechanical back pain. By enabling earlier, more precise diagnosis and better disease management, we empower clinicians and patients with the tools to take control of disease and improve long-term outcomes.

March is Autoimmune Awareness Month.Autoimmune diseases are complex, often invisible, and frequently misunderstood. Dela...
03/04/2026

March is Autoimmune Awareness Month.

Autoimmune diseases are complex, often invisible, and frequently misunderstood. Delayed recognition can mean years without clear answers.

At Augurex, we are committed to reducing diagnostic delay and advancing biomarker-driven tools that support earlier identification of inflammatory disease and improved patient outcomes.

Greater awareness leads to better care.

Neil Klompas, CEO and President of Augurex, will be attending the TD Cowen 2026 Healthcare Conference in Boston, March 2...
02/25/2026

Neil Klompas, CEO and President of Augurex, will be attending the TD Cowen 2026 Healthcare Conference in Boston, March 2–4.

If you are attending and would like to connect to discuss Augurex’s diagnostic portfolio and growth strategy, please reach out to coordinate a meeting.

We look forward to engaging with investors and partners during the conference.

February 2 marks Rheumatoid Arthritis (RA) Awareness Day, a time to recognize the millions of people around the world li...
02/03/2026

February 2 marks Rheumatoid Arthritis (RA) Awareness Day, a time to recognize the millions of people around the world living with RA, a chronic autoimmune disease that affects far more than just the joints.

RA can bring daily pain, fatigue, and other challenges that are often invisible to others. With continued research, early diagnosis, and advances in treatment, we can help improve quality of life for everyone affected by RA.

At Augurex, we are proud to highlight our work in RA and our ongoing commitment to advancing diagnostic solutions that support rheumatologists and patients in improving outcomes and managing disease more effectively.

Let’s listen, support, and raise awareness. Because no one should have to navigate RA alone.

We’re honored to be featured by Moira Gunn of NPR’s BioTech Nation as one of her Top 5 JPM interviews.In this special JP...
01/13/2026

We’re honored to be featured by Moira Gunn of NPR’s BioTech Nation as one of her Top 5 JPM interviews.

In this special JPM edition, Augurex was highlighted alongside four other companies shaping the future of biotech, with a focus on our work to reduce diagnostic delay in chronic back pain and axial spondyloarthritis, where patients often wait 7–10 years for the right diagnosis.

Thank you to Moira Gunn and BioTech Nation for the opportunity to share how Augurex is changing the diagnostic journey for patients who deserve answers sooner.

Listen to the interview here: https://podcasts.apple.com/us/podcast/youve-had-back-pain-for-7-10-years-neil-klompas-ceo-augurex/id876041079?i=1000744703417

We’re proud to share that the Spondylitis Association of America (SAA) has featured Augurex’s research from the America...
12/03/2025

We’re proud to share that the Spondylitis Association of America (SAA) has featured Augurex’s research from the American College of Rheumatology (ACR) Convergence 2025 conference in a new article and in their recent eSUN newsletter.

Both pieces spotlight new findings on SPINEstat® (Anti-14-3-3eta Multiplex test) and its potential to improve early and accurate diagnosis of axial spondyloarthritis (axSpA), a chronic inflammatory condition that is often difficult to identify in its early stages.

Through their coverage, SAA continues to deliver trusted education to the spondyloarthritis community, including raising awareness of innovations that can shorten diagnostic delays and guide timely, personalized care.

SAA’s recognition underscores our commitment to ending diagnostic delays in axSpA and supporting patients and their physicians in achieving better outcomes.

🔗 Read the full article: https://spondylitis.org/research-new/new-research-highlights-promising-advances-in-axspa-diagnosis/

We’re excited to share that Neil Klompas, Augurex CEO and President, joined the Progress, Potential, And Possibilities P...
11/25/2025

We’re excited to share that Neil Klompas, Augurex CEO and President, joined the Progress, Potential, And Possibilities Podcast to discuss how tools like SPINEstat® can help improve early detection and referral accuracy in axial spondyloarthritis (axSpA).

In this episode, “Ending Diagnostic Delays in Autoimmune Conditions,” Neil highlights how SPINEstat® supports clinicians in distinguishing inflammatory axSpA from mechanical back pain, addressing a key contributor to the long diagnostic delay patients often experience.

🎧 Listen to the full episode:
https://www.progresspotentialpossibilities.com/podcast/episode/7961baa0/neil-klompas-ceo-augurex-ending-diagnostic-delays-in-autoimmune-conditions

We are pleased to share that Dr. Norma Kor, Augurex Co-founder and Board Chair, was featured on the Spondylitis Associat...
11/24/2025

We are pleased to share that Dr. Norma Kor, Augurex Co-founder and Board Chair, was featured on the Spondylitis Association of America’s Spondycast Podcast.

In this episode, Dr. Biln discusses how new biomarkers, patient questionnaires, and tools like SPINEstat® (Anti-14-3-3eta Multiplex) can help close the long diagnostic delay in axial spondyloarthritis (axSpA) by improving early detection and referral accuracy, particularly in primary care settings.

🎧 Listen to the full episode: https://spondylitis.org/podcasts/episode-121-closing-the-diagnosis-delay-in-spondyloarthritis/

We’re pleased to share that the 14-3-3eta test for rheumatoid arthritis (RA) will launch through Sonic Reference Laborat...
11/17/2025

We’re pleased to share that the 14-3-3eta test for rheumatoid arthritis (RA) will launch through Sonic Reference Laboratory in the United States on December 15, 2025.

This launch expands access to a blood test that enables earlier RA diagnostic and prognostic insights and more precise ongoing monitoring, giving patients and their healthcare providers a clearer view of disease progression and treatment response.

With Sonic Healthcare USA’s national reach and commitment to diagnostic excellence, this agreement represents another important step in Augurex’s deepening commitment in making advanced RA testing broadly accessible and improving outcomes for patients across the U.S. and around the world.

Read more in our press release: https://augurex.com/augurex-life-sciences-corp-announces-the-launch-of-the-14-3-3eta-test-for-rheumatoid-arthritis-diagnosis-and-monitoring-with-sonic-reference-laboratory/

November 2–8 is National Pain Awareness Week, a time to recognize the millions of people living with chronic pain from c...
11/02/2025

November 2–8 is National Pain Awareness Week, a time to recognize the millions of people living with chronic pain from conditions like rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA).

At Augurex, we stand with patients and clinicians working toward earlier diagnosis and better management of inflammation-driven pain. Through innovative biomarker-based diagnostics such as JOINTstat® for RA and SPINEstat® for axSpA, we help enable earlier detection of disease activity to support timely treatment decisions before pain leads to lasting joint or spinal damage.

Together, we can raise awareness, improve understanding, and help drive earlier, more targeted care for those affected by chronic inflammatory pain.

We’re excited to see RheumNow highlight Dr. Atul Deodhar’s perspective on biomarker discovery in axial spondyloarthritis...
10/31/2025

We’re excited to see RheumNow highlight Dr. Atul Deodhar’s perspective on biomarker discovery in axial spondyloarthritis (axSpA) in their coverage from ACR Convergence 2025 in Chicago.

In this segment, Dr. Deodhar reviews Augurex’s new data presentations (one oral and two posters), which showcased promising data on the Anti-14-3-3eta Multiplex Immunoassay Test improving early detection and aiding in more accurate clinical decision-making in patients with axSpA. In particular, the data highlighted the Anti-14-3-3eta Multiplex Test complementing HLA-B27 and CRP, helping physicians better differentiate axSpA from mechanical back pain to support earlier, more confident diagnosis.

🎥 Watch RheumNow’s full coverage here: https://www.youtube.com/watch?v=X8Sc_3oBSVA

RheumNow’s on-the-ground coverage at the ACR 2025 conference featured Augurex’s new data on the Anti-14-3-3eta Multiplex...
10/28/2025

RheumNow’s on-the-ground coverage at the ACR 2025 conference featured Augurex’s new data on the Anti-14-3-3eta Multiplex Immunoassay Test in axSpA and mechanical back pain patients.

In the segment, Dr. Akhil Sood highlights that “the biomarker can distinguish who has axSpA and who does not, and this is a promising step toward a simple diagnostic tool.”

This recognition underscores the growing clinical relevance of SPINEstat® (Anti-14-3-3eta Multiplex Immunoassay Test) in supporting earlier and more accurate clinical decision-making in axial spondyloarthritis (axSpA).

🎥 Watch the RheumNow coverage here: https://www.youtube.com/watch?v=EvKv45qybDo

We are pleased to share that the U.S. FDA has granted Breakthrough Device Designation for SPINEstat® (14-3-3eta Autoanti...
10/28/2025

We are pleased to share that the U.S. FDA has granted Breakthrough Device Designation for SPINEstat® (14-3-3eta Autoantibody Multiplex Immunoassay Test) - Augurex’s first-in-class blood test to aid in the diagnosis of patients with axial spondyloarthritis (axSpA).

Breakthrough designation recognizes the significant unmet need in early and accurate axSpA diagnosis, where patients often face long delays before receiving appropriate care.

SPINEstat® detects autoantibodies to the 14-3-3eta protein. In combination with clinical findings, signs and symptoms, SPINEstat® may aid in the differentiation of patients with axSpA from those with mechanical back pain, to support earlier, more confident clinical decision making and diagnosis.

🔗 Read the full press release on our website: https://augurex.com/augurex-life-sciences-granted-fda-breakthrough-designation-for-spinestat-its-first-in-class-diagnostic-test-for-axial-spondyloarthritis/

Address

887 Great Northern Way, Suite 220
Vancouver, BC
V5T4T5

Telephone

+16046373280

Website

Alerts

Be the first to know and let us send you an email when Augurex Life Sciences Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Augurex Life Sciences Corp.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Augurex is a biotech company that is focused on developing biomarker blood tests that transform patient clinical management for better disease outcomes.